Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma

The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely do tumours regress completely. Frequently, the reason for this is that therapies targeting specific onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Saei, Azad, Eichhorn, Pieter Johan Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721815/
https://www.ncbi.nlm.nih.gov/pubmed/31416288
http://dx.doi.org/10.3390/cancers11081176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721815/
https://www.ncbi.nlm.nih.gov/pubmed/31416288
http://dx.doi.org/10.3390/cancers11081176

Ejemplares similares